Arginase in patients with breast cancer

Porembska, Zofia; Luboiński, G; Chrzanowska, Alicja; Mielczarek, Magdalena; Magnuska, Joanna; Barańczyk‐Kuźma, Anna

doi:10.1016/s0009-8981(02)00391-1

Cited by 65 publications

(52 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We demonstrated that the mean arginase activity was significantlyhigherintheplasmaofthebreastcancerpatients comparedtothe42healthyvolunteers.Interestingly,astatistically significant increase in arginase activity was only observed in patients with a later disease stage compared to healthyvolunteers(p<0.05).Theseresultssupportprevious reports that demonstrated higher arginase activity in breast cancer patients [20][21][22][23], and show an association between arginaseactivityandlaterstagesofthedisease.Becausethe differences in plasma arginase activity was not significant in patientsofstagesIandII,theuseofthisenzymaticactivityas amarkerofmammarycarcinomaisworthfurtherdiscussion.…”

Section: Discussionsupporting

confidence: 87%

“…This result is consistent with a previous report that showed higher arginase activity in the plasma of cancer patients [20][21][22][23]. Because the increase in arginase activity was detected only when comparing healthy volunteers and breast cancer patients, we analyzed whether this difference could be correlated with disease stage.…”

Section: Arginase Activity In Plasmasupporting

confidence: 91%

See 1 more Smart Citation

Arginase Activity in Patients with Breast Cancer: An Analysis of Plasma, Tumors, and Its Relationship with the Presence of the Estrogen Receptor

Perez

Olivares²,

Rodriguez

et al. 2012

Onkologie

View full text Add to dashboard Cite

Background: Breast cancer is an important cause of cancerrelated death in women. In this pathological condition, arginase plays a role by providing ornithine as a substrate for the biosynthesis of polyamines which are important in tumor progression. The aim of this work was to determine the arginase activity in the plasma and tumors of patients with breast cancer; also, we investigated the relationship between this activity and the presence of the estrogen receptor. Patients and Methods: We evaluated the plasma arginase activity levels in 80 women with breast cancer and 42 healthy control subjects. We also measured the arginase levels in 42 breast cancer biopsies and 42 control tissues. Results: The mean activity of arginase in plasma was higher in breast cancer patients (0.78 nM/min/mg protein ± 0.04; p = 0.001) than in healthy volunteers (0.53 nM/ min/mg protein ± 0.04); however, this difference was indicative of patients in the advanced stages of the disease (n = 38, stage III; p < 0.0001). In addition, we did not find a relationship between the estrogen receptor and arginase activity. Conclusion: Our results show a higher arginase activity in the plasma of patients in the advanced stages of the disease, suggesting that arginase activity could serve as a possible biological marker of breast cancer progression.

show abstract

Section: Discussionsupporting

confidence: 87%

Section: Arginase Activity In Plasmasupporting

confidence: 91%

Arginase Activity in Patients with Breast Cancer: An Analysis of Plasma, Tumors, and Its Relationship with the Presence of the Estrogen Receptor

Perez

Olivares²,

Rodriguez

et al. 2012

Onkologie

View full text Add to dashboard Cite

show abstract

“…The function of ARG2 is not fully understood, but high levels of ARG2 have been described in tumors and cell lines (27,28). ARG2 was recently found overexpressed in cell lines derived from spontaneous murine mammary tumor and pulmonary metastases, and the authors suggested that ARG2 play a major role in tumor angiogenesis (29).…”

Section: Discussionmentioning

confidence: 99%

Diagnosis of Suspicious Thyroid Nodules Using Four Protein Biomarkers

Cerutti

Latini²,

Nakabashi³

et al. 2006

Clinical Cancer Research

View full text Add to dashboard Cite

Purpose: Fine-needle aspiration (FNA) cytology, a standard method for thyroid nodule diagnosis, cannot distinguish between benign follicular thyroid adenoma (FTA) and malignant follicular thyroid carcinoma (FTC). Previously, using expression profiling, we found that a combination of transcript expression levels from DDIT3, ARG2, C1orf24, and ITM1 distinguished between FTA and FTC. The goal of this study was to determine if antibody markers used alone or in combination could accurately distinguish between a wider variety of benign and malignant thyroid lesions in fixed sections and FNA samples. Experimental Design: Immunohistochemistry wasdoneon27FTA, 25FTC,and75otherbenign and malignant thyroid tissue sections using custom antibodies for chromosome 1open reading frame 24 (C1orf24) and integral membrane protein 1 (ITM1) and commercial antibodies for DNA damage^inducible transcript 3 (DDIT3) and arginase II (ARG2). FNA samples were also tested usingthe sameantibodies.RNA expressionwasmeasuredbyquantitative PCRin 33thyroidlesions. Results: C1orf24 and ITM1antibodies had an estimated sensitivity of 1.00 for distinguishing FTA from FTC. For the expanded analysis of all lesions studied, ITM1 had an estimated sensitivity of 1.00 for detecting malignancy. Because all four cancer biomarkers did well, producing overlapping confidence intervals, not one best marker was distinguished. Transcript levels also reliably predicted malignancy, but immunohistochemistry had a higher sensitivity. Malignant cells were easily detected in FNA samples using these markers. Conclusions: Weimprovedthis diagnostic testbyadding C1orf24 and ITM1customantibodies and showing use on a wider variety of thyroid pathology.We recommend that testing of all four cancer biomarkers now be advanced tolarger trials. Use of one or more of these antibodies shouldimprove diagnostic accuracy of suspicious thyroid nodules from both tissue sections and FNA samples.

show abstract

“…Arginase II has been reported to be overexpressed in cancerous tissues in general (Harris et al, 1983;Leu and Wang, 1992;Suer Gokmen et al, 1999;del Ara et al, 2002;Porembska et al, 2003) and it is well established that this gene is overexpressed in gastric adenocarcinomas (Wu et al, 1996). Since ARG2 catalyses the conversion of arginine to ornithine, a crucial metabolite in biosynthesis of glutamic acid, proline and polyamines (Vockley et al, 1996), an increase in the level of arginase may reflect accelerated metabolism due to cell proliferation or tumour growth.…”

Section: Discussionmentioning

confidence: 99%

Differential gene-expression profiles associated with gastric adenoma

et al. 2004

View full text Add to dashboard Cite

Gastric adenomas may eventually progress to adenocarcinomas at varying rates. The purpose of the present study was to identify gene-expression profiles linked to the heterogeneous nature of gastric adenoma as compared to adenocarcinoma. Suppression subtractive hybridisation analysis was performed to extract relevant genes from two cases of low-and high-grade gastric adenomas. The identified genes were quantified by RT -PCR in 14 low-grade adenoma, nine high-grade adenoma and nine adenocarcinoma samples, followed by hierarchical clustering analysis to separate tumours into groups according to their gene-expression profiles. Nine genes previously implicated in carcinogenesis in a variety of organs, including three genes related to gastric adenocarcinoma, were identified. The overexpression of these genes in gastric adenoma has not been reported previously. The clustering analysis of these nine genes across 32 cases identified three groups, one of which consisted primarily of adenocarcinomas, whereas the other two groups consisted of adenomas. One group of adenomas, characterised by larger tumour size, exhibited gene-expression profiles of an intestinal cell lineage implicated in the pathogenesis of an intestinal-type gastric adenocarcinoma. Another adenoma group consisting of low-grade adenomas with smaller tumour size exhibited a unique expression profile. In conclusion, clustering analysis of expression profiles using a limited number of genes may serve as molecular markers for gastric adenoma with different biological properties. Although the prognostic values of these gene-expression profiles need to be evaluated in further follow-up study of adenoma cases, these findings add new insights to (a) our understanding of the pathogenesis of gastric tumours, (b) the development of specific tumour markers for clinical practice, and (c) the design of novel therapeutic targets.

show abstract

Arginase in patients with breast cancer

Cited by 65 publications

References 15 publications

Arginase Activity in Patients with Breast Cancer: An Analysis of Plasma, Tumors, and Its Relationship with the Presence of the Estrogen Receptor

Arginase Activity in Patients with Breast Cancer: An Analysis of Plasma, Tumors, and Its Relationship with the Presence of the Estrogen Receptor

Diagnosis of Suspicious Thyroid Nodules Using Four Protein Biomarkers

Differential gene-expression profiles associated with gastric adenoma

Contact Info

Product

Resources

About